# Primerica Schedules Second Quarter 2026 Financial Results Webcast
Canonical URL: https://biopharmsignal.com/news/PRI/primerica-schedules-second-quarter-2026-financial-results-webcast-8557ad05
Ticker: PRI
Company: PRIMERICA
Source: PRIMERICA
Published: 2026-07-15 20:15 EST
Original Source URL: https://investors.primerica.com/news-events/press-releases/detail/380/primerica-schedules-second-quarter-2026-financial-results
## Summary

DULUTH, Ga.--(BUSINESS WIRE)-- Primerica, Inc. (NYSE:PRI) announced today that it will hold a webcast on Thursday, August 6, 2026, at 10:00…...

## Article Body
DULUTH, Ga.--(BUSINESS WIRE)-- Primerica, Inc. (NYSE:PRI) announced today that it will hold a webcast on Thursday, August 6, 2026, at 10:00 a.m. (ET) to discuss the Company’s results for the quarter ended June 30, 2026, as well as other business-related matters, including future expectations. A news release announcing the quarter’s results will be distributed after the close of the market on Wednesday, August 5, 2026.

The earnings news release, financial supplement and live webcast will be available on the Primerica Investors website at https://investors.primerica.com . A replay of the call will be available for approximately 30 days.

About Primerica, Inc.

Primerica, Inc. is a leading diversified financial services distribution company serving middle-income households in the United States and Canada. Our licensed representatives educate families on how to prepare for a more secure financial future and help them achieve their financial goals with our term life insurance and third-party mutual funds, managed accounts, annuities, loans and other financial products. We insured over 5.5 million lives and had approximately 3.1 million client investment accounts as of December 31, 2025. Through our life insurance subsidiaries in North America, in 2025 Primerica was the #3 issuer of term life insurance, which we largely reinsure. Primerica stock is included in the S&P MidCap 400 and the Russell 1000 stock indices and is traded on The New York Stock Exchange under the symbol “PRI”. We are headquartered in Duluth, Georgia.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260714154550/en/

Investor Contact: Nicole Russell

470-564-6663

Email: Nicole.Russell@primerica.com

Media Contact: Susan Chana

404-229-8302

Email: susan.chana@primerica.com

Source: Primerica, Inc.

Released July 15, 2026
## Recent Company News
- 2026-07-15 20:15 EST — [Primerica Schedules Second Quarter 2026 Financial Results Webcast](https://biopharmsignal.com/news/PRI/primerica-schedules-second-quarter-2026-financial-results-webcast-8557ad05) — Source: PRIMERICA
- 2026-06-30 04:00 EST — [PRIMERICA HOUSEHOLD BUDGET INDEX™ (HBI™): Gas Prices Continued to Weigh on Purchasing Power of Middle-Income Families in May](https://biopharmsignal.com/news/PRI/primerica-household-budget-index-hbi-gas-prices-continued-to-weigh-on-purchasing-cd4ad354) — Source: PRIMERICA
- 2026-06-25 13:46 EST — [Survey Reveals 85% of Canadians Trust Professional Financial Advice Over Social Media “Finfluencers”](https://biopharmsignal.com/news/PRI/survey-reveals-85-of-canadians-trust-professional-financial-advice-over-social-media-finfluencers) — Source: PRIMERICA
- 2026-06-25 13:46 EST — [PRIMERICA HOUSEHOLD BUDGET INDEX™ (HBI™): Rising Gas Prices Limit Purchasing Power of Middle-Income Americans in April](https://biopharmsignal.com/news/PRI/primerica-household-budget-indextm-hbitm-rising-gas-prices-limit-purchasing-power-of-middle-income-americans-in-april) — Source: PRIMERICA
- 2026-06-25 13:46 EST — [Primerica Reports First Quarter 2026 Results](https://biopharmsignal.com/news/PRI/primerica-reports-first-quarter-2026-results) — Source: PRIMERICA
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)